Recordati Rare Diseases, Inc.
Recordati Rare Diseases, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2011, the company has rapidly established itself as a leader in developing and commercialising innovative treatments for rare diseases, focusing on areas such as metabolic disorders and genetic conditions. With a portfolio that includes unique therapies tailored to meet the needs of patients with rare conditions, Recordati Rare Diseases stands out for its commitment to addressing unmet medical needs. The company has achieved significant milestones, including strategic partnerships and the successful launch of several key products that have positively impacted patient lives. Recognised for its dedication to rare disease research, Recordati Rare Diseases continues to strengthen its market position through ongoing innovation and patient-centric initiatives.
DitchCarbon Score
How does Recordati Rare Diseases, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Recordati Rare Diseases, Inc.'s score of 30 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Recordati Rare Diseases, Inc.'s reported carbon emissions
Recordati Rare Diseases, Inc., headquartered in the US, currently does not have publicly available data regarding its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This absence of data suggests that the company may still be in the early stages of formalising its climate commitments or reporting on its environmental impact. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction strategies, indicating a growing trend towards accountability in emissions management.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Recordati Rare Diseases, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
